[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"venous-thromboses\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:venous-thromboses":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,59,85,120,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":4},"100634355","the-gore-viabahn-fortegra-venous-stent-post-approval-study-100634355",false,"NCT07538609","The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study","Preoperative Inclusion Criteria:\n\n* Presence of a lesion necessitating treatment with the GORE® VIABAHN® FORTEGRA Venous Stent, as previously determined by an investigator\u002Fsub-investigator.\n* Patient is at least 18 years of age.\n* Patient is willing and able to comply with all follow-up evaluations as well as any required medication or compression regimen.\n* Patient is able to provide informed consent themself.\n\nIntraoperative Inclusion Criteria:\n\n* Patient can accommodate an appropriately sized GORE® VIABAHN® FORTEGRA Venous Stent as per reference vessel diameter (see IFU), as determined by intraoperative IVUS post pre-dilation.\n* Patient must have appropriate access vessels to accommodate the delivery sheath for the selected device size.\n* Patient has adequate landing zones free from significant disease requiring treatment beyond the proximal and distal margins of the lesion.\n* Patient has adequate inflow\u002Foutflow to\u002Ffrom the target lesion(s), per investigator\u002Fsub- investigator discretion.\n* Lesion can be traversed with a guidewire.\n\nIntraoperative Exclusion Criteria:\n\n* Patient is contraindicated for treatment with the GORE® VIABAHN® FORTEGRA Venous Stent according to the IFU.","ALL","18 Years",{"count":18,"type":19},150,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study is a prospective, multicenter, single-arm post-market clinical study to evaluate the GORE® VIABAHN® FORTEGRA Venous Stent in real-world use.",[25,26,27,28,29,30,31,32],"Venous Thromboses","Venous Disease","Venous Leg Ulcer","Venous Stasis","Venous Ulcer","Venous Stenosis","Venous Occlusion","Vein Thrombosis",[34,35,36,30,37,38,39,40,41,42,26,43,44,45,46],"Vein Stent","VIAFORT","Venous Thrombosis","Gore","Venous occlusion","VIABAHN FORTEGRA","FORTEGRA","Deep Venous Insufficiency","Deep venous","DVT Treatment","Venous Stent","Venous insufficiency treatment options","Venous disease treatment options","NOT_YET_RECRUITING","2026-05-11",{"date":50,"type":51},"2026-05-14","ACTUAL",{"date":53,"type":19},"2026-10-07",{"date":55,"type":19},"2031-05",{"name":57,"class":58},"W.L.Gore & Associates","INDUSTRY",{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":20,"phases":68,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100476872","the-gore-viabahn-fortegra-venous-stent-iliofemoral-study-100476872","NCT05489588","The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study","Evaluation of the GORE® VIAFORT Vascular Stent for Treatment of Symptomatic Iliofemoral Venous Obstruction","Preoperative Inclusion Criteria:\n\n* Patient is at least 18 years of age.\n* Patient is willing and able to comply with all follow-up evaluations as well as any required medication or compression regimen.\n* Patient is able to provide informed consent.\n* One of the following: Clinical severity class of CEAP 'C' classification ≥3 or rVCSS pain score ≥2.\n* Intention to treat the target areas with only the GORE® VIAFORT Vascular Stent.\n* Estimated life expectancy ≥1 year.\n* Patient is ambulatory (use of assistive walking device such as a cane or walker is acceptable).\n* Patient has adequate inflow to the target lesion(s), per investigator\u002Fsub-investigator discretion, involving at least a patent femoral or deep femoral vein.\n* Presence of non-malignant symptomatic unilateral iliofemoral venous obstruction.\n\nPreoperative Exclusion Criteria:\n\n* Patient has DVT in the target areas with symptom onset date greater than 14 days but less than or equal to 90 days prior to treatment.\n* Patient is a pregnant or breastfeeding woman, or a woman planning to become pregnant through the 12-month visit.\n* Patient has clinically significant (e.g., symptoms of chest pain, hemoptysis, dyspnea, hypoxia, etc.) pulmonary embolism (confirmed via Computed Tomography Angiography) at the time of enrollment.\n* Patient has a known uncorrectable bleeding diathesis or active coagulopathy meeting the following definitions (all must be tested for):\n\n  1. uncorrected INR\\>2 (not as a result of warfarin or DOAC therapy), OR\n  2. platelet count \\\u003C50,000 or \\>1,000,000 cells\u002Fmm3, OR\n  3. white blood cell count \\\u003C3,000 or \\>12,500 cells\u002Fmm3\n* Patient has impaired renal function (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2) or is currently on dialysis.\n* Patient has uncorrected hemoglobin of \\\u003C9 g\u002FdL.\n* Patient has known history of antiphospholipid syndrome (APS).\n* Patient has known homozygous or acquired coagulation defect (e.g., Protein C or Protein S deficiency) that cannot be treated with therapeutic anticoagulation.\n* Patient has a planned surgical intervention that has the potential to clinically interfere with the endpoints of this treatment (other than pre-stenting procedures such as thrombolysis or thrombectomy) within 30 days prior to or within 30 days after the planned study procedure. Examples include surgical interventions that may impact mobility, and surgical interventions that require cessation of therapeutic antiplatelet or anticoagulation within 30 days following the index procedure.\n* Patient has had or requires open deep venous surgery in the target limb.\n* Patient is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this treatment, in the opinion of the investigator\u002Fsub-investigator. Observational studies are permitted.\n* Patient has had a previous major (i.e., above the ankle) amputation of the target lower limb.\n* Patient has known sensitivity to device materials.\n* Patient has had prior stenting or grafts in the target vessels.\n* Patient has a known or suspected active systemic infection at the time of the index procedure. Patients with a chronic infection (e.g., HIV, hepatitis C) that can be managed, and with an active clinical plan in place may be eligible.\n* Patient has known history of intravenous drug abuse within one year of treatment.\n* Patient has significant peripheral arterial disease (chronic Rutherford Type 2 or greater, acute Rutherford Type IIa or greater).\n* Patient has a BMI \\>45. Patients with a BMI of up to 45 may be enrolled provided that diagnostic quality ultrasound of the implant sites can be performed.\n* Patient is actively undergoing or plans to begin cancer treatment.\n* Patients with hypercoagulable states that are unwilling to take anticoagulant medications on a long-term basis.\n* Patient has contraindication to thrombolytics, anticoagulants, or iodinated contrast necessary for the index procedure and long-term medical therapy (contrast pre-medication is acceptable).\n\nIntraoperative Inclusion Criteria:\n\n* Presence of non-malignant unilateral obstruction of the common femoral vein, external iliac vein, and\u002For common iliac vein defined as occlusion or at least 50% reduction in target vessel lumen as measured by procedural IVUS and venogram.\n* Patient can accommodate an appropriately sized GORE® VIAFORT Vascular Stent as per reference vessel diameter (see IFU), as determined by intraoperative IVUS post pre-dilation.\n* Patient must have appropriate access vessels to accommodate the delivery sheath for the selected device size.\n* Patient has adequate landing zones free from significant disease requiring treatment within the native vessels beyond the proximal and distal margins of the lesion.\n* Patient has adequate inflow to the target lesion(s), per investigator\u002Fsub-investigator discretion, involving at least a patent femoral or deep femoral vein.\n* Lesion can be traversed with a guidewire.\n* Disease involves only unilateral iliofemoral venous segments with intent to stent all affected iliofemoral segments. Patients with disease extending into the inferior vena cava or contra-lateral iliofemoral veins who are anticipated to require endovascular or surgical treatment within 12 months after investigational device implant will be excluded.\n* Patient does not have significant (i.e., \\>20% residual thrombosis) acute thrombus within the target stent area at the time of investigational device placement. Patients with acute thrombus within the target stent area must have thrombus successfully treated prior to investigational device placement. Successful thrombus treatment is defined as reestablishment of antegrade flow with ≤20% residual thrombosis as confirmed by IVUS and venogram, AND freedom from bleeding, vascular injury, or hemodynamically significant pulmonary embolism. After successful thrombus treatment, investigational device placement can occur within the same procedure.",{"count":67,"type":19},165,[22],"This study is a prospective, non-randomized, multicenter, single-arm, clinical study to evaluate the performance, safety and efficacy of the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) for treatment of symptomatic iliofemoral venous obstruction.",[25,26,27,28,29,30,31,32,71,72],"Vein Occlusion","Vein Disease",[35,34,36,30,37,31,40,39,26,41,74,42,43,44,45],"Venous disease treatment Options","RECRUITING","2026-04-07",{"date":78,"type":51},"2026-04-09",{"date":80,"type":51},"2023-03-02",{"date":82,"type":19},"2031-03",{"name":57,"class":58},27,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":20,"phases":95,"briefSummary":97,"conditions":98,"keywords":102,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":119},"100560808","phase-4-individual-targeted-thrombosis-prophylaxis-versus-the-standard-one-size-fits-all-approach-in-patients-undergoing-total-hip-or-total-knee-replacement-100560808","NCT06581965","inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","The DISTINCT Trial: inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT: a National, Multicenter, Randomized, Multi-arm, Open-label Trial.","DISTINCT","Inclusion Criteria:\n\n* Scheduled to undergo an elective total hip arthroplasty or total knee arthroplasty\n* Aged 18 years or older\n\nExclusion Criteria:\n\n* Primary arthroplasty for fractures\n* Revision surgery\n* Hemiarthroplasty\n* Pregnancy\n* Current use of therapeutic anticoagulant therapy of any type (e.g., LMWH, DOAC, vitamin K antagonist)\n* A contraindication for either study drug\n* Insufficient knowledge of the Dutch language\n* Insufficient mental or physical ability to fulfil trial requirements\n* Active malignancy (i.e. cancer diagnosis within six months before surgery (excluding basal-cell or squamous-cell carcinoma of the skin), recently recurrent or progressive cancer or any cancer that required anti-cancer treatment within six months before surgery)\n* Patients using thrombocyte aggregation inhibitors that cannot be temporarily discontinued at the discretion of their treating physician",{"count":94,"type":19},10078,[96],"PHASE4","After hip or knee replacement all patients receive a standardized treatment with blood thinners, this medication is called thrombosis prophylaxis. However, despite this standard treatment some individuals still develop venous thrombosis (VTE), while others experience bleeding. This indicates that not all patients have the same VTE risk following surgery. Individualizing the amount of thrombosis prophylaxis following surgery might lead to less thrombotic and bleeding events. In this study the investigators individualize the treatment with thrombosis prophylaxis based on the medical history of a patient.\n\nThe main questions this study aims to answer are:\n\nCan thrombosis prophylaxis be shortened in patients with a low VTE risk to decrease the risk of bleeding without increasing the risk of VTE? Does an increase in the dose and duration of thrombosis prophylaxis in patients with a high VTE risk reduce the risk of VTE without inducing an unacceptable risk of bleeds?\n\nResearchers will compare both the shortened treatment in low VTE risk patients and the intensified and extended treatment in high VTE risk patients with the standard treatment to assess the risk of VTE and bleeding in comparison to the standard treatment.\n\nParticipants will receive 4 questionnaires to evaluate whether they have experienced a VTE or bleed. For this study no additional hospital visits are necessary.",[99,25,100,101],"Venous Thromboembolism","Pulmonary Embolism","Deep Vein Thrombosis",[103,104,105,106,107,108],"Venous thromboembolism","Prophylaxis","Individualized Medicine","Total hip arthroplasty","Total knee arthroplasty","Randomized controlled trial","2025-08-26",{"date":111,"type":51},"2025-09-03",{"date":113,"type":51},"2024-11-11",{"date":115,"type":19},"2031-02-01",{"name":117,"class":118},"Leiden University Medical Center","OTHER",10,{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":126,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":15,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":20,"phases":131,"briefSummary":132,"conditions":133,"keywords":137,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},"100493900","clonal-hematopoiesis-and-nets-formation-in-venous-thrombosis-clodette-100493900","NCT05711173","Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)","Role of Clonal Hematopoiesis and NETs Formation in Unusual Venous Thrombosis (CLODETTE)","CLODETTE","Inclusion Criteria:\n\n* Patients (male or female) less than 50 y.o with :\n* Splanchnic venous territory thrombosis or\n* Cerebral venous thrombosis or\n* Venous thrombosis of the upper limb or\n* Pulmonary embolism (1st episode if male, 2nd episode if female) unprovoked or\n* 1 episode of deep vein thrombosis + 1 episode of arterial thrombosis\n\nExclusion Criteria:\n\n* Presence of a major or minor transient venous thrombosis risk factor:\n* Surgery within the last 3 months preceding the qualifying thrombotic episode\n* Lower limb fracture with immobilization \\> 3 days in the last 3 months preceding the qualifying thrombotic episode\n* Presence of estro-progestational contraception\n* Pregnancy\n* Immobilization for acute medical reasons within the last 3 months preceding the qualifying thrombotic episode\n* Air or car travel \\> 6 hours\n* Presence of a major or minor persistent risk factor for venous thrombosis:\n* Presence of active cancer (solid cancer or hematologic malignancy)\n* Chronic inflammatory digestive or joint diseases\n* Ongoing treatment with heparin (low molecular weight heparin (LMWH) or unfractionated heparin (UFH))\n* Presence of an abnormality on the thrombophilia test among the following abnormalities\n* Protein C deficiency\n* Protein S deficiency\n* Anti-thrombin deficiency\n* Heterozygous or homozygous factor II mutation\n* Heterozygous or homozygous factor V mutation\n* Presence of anti-phospholipid syndrome\n* Presence of myeloproliferative neoplasia\n* Presence of paroxysmal nocturnal hemoglobinuria","6 Years","50 Years",{"count":18,"type":19},[22],"Thrombo-embolic venous diseases are represented by deep venous thrombosis and\u002For pulmonary embolism. In some patients with repeated thrombosis or occurrence of thrombosis in unusual sites, the etiological workup remains negative, which represents a problem for the management of the anticoagulant treatments. Recently, two factors have been identified as important in the physiopathology of hemostasis and coagulation: the presence of clonal hematopoiesis of indetermined potential (CHIP) and the formation of neutrophil extracellular traps (NETs). In this study, these two factors will be studied in patients with repeated venous thrombosis or thrombosis occurring in unusual site.",[25,134,135,136],"Thromboembolic Disease","Neutrophil Extracellular Trap Formation","Clonal Hematopoiesis of Indeterminate Potential",[138,139,140],"Thrombosis","Venous thrombosis","Clonal hematopoiesis of indetermined potential","2025-03-20",{"date":143,"type":51},"2025-03-21",{"date":145,"type":51},"2023-03-03",{"date":147,"type":19},"2027-03",{"name":149,"class":118},"University Hospital, Bordeaux",7,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":20,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100550843","phase-4-tranexamic-acid-to-decrease-heavy-menstrual-bleeding-in-individuals-anticoagulated-for-venous-thromboembolism-pilot-study-100550843","NCT06452342","TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study","T-REX HMB","Inclusion Criteria:\n\n1. Adult pre-menopausal individuals with regular menstrual cycles (defined as menstrual bleeding every 24 to 38 days)\n2. Diagnosed with acute VTE on objective imaging;\n3. Within two weeks of starting treatment with therapeutic dose anticoagulation;\n4. Planned treatment of at least 3 months of therapeutic dose anticoagulation.\n5. Written informed consent in accordance with federal, local and institutional guidelines.\n\nExclusion Criteria:\n\n1. Hypersensitivity or allergy to TXA\n2. Active major bleeding other than menstrual bleeding\n3. Use of hormonal contraceptives\n4. Known history of thrombosis and antiphospholipid syndrome (including those patients that are triple positive for lupus anticoagulant, anticardiolipin antibodies, and anti-beta 2-glycoprotein I antibodies.\n5. Known renal insufficiency\n6. Pregnant or breastfeeding\n7. Use of other thrombotic agents\n8. Under 18 years of age\n9. Patient is unable to provide informed consent (lacking capacity, language etc)","99 Years",{"count":160,"type":19},20,[96],"T-REX HMB is a pilot randomized controlled trial (RCT) designed to assess the feasibility of a full trial comparing tranexamic acid (TXA) to placebo in decreasing HMB in premenopausal individuals anticoagulated for VTE. Strong data supports TXA as an effective and safe agent at decreasing HMB in the general population, but its use in those with VTE has been limited by a lack of data for its efficacy in anticoagulated individuals and theoretical concerns of its prothrombotic effects.",[99,25,164,165],"Heavy Menstrual Bleeding","Anticoagulants and Bleeding Disorders","2024-06-10",{"date":168,"type":51},"2024-06-12",{"date":170,"type":19},"2024-06",{"date":172,"type":19},"2026-04",{"name":174,"class":118},"University Health Network, Toronto"]